Douglas Seals
Concepts (780)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 202 | 2026 | 1963 | 20.640 |
Why?
| | Endothelium, Vascular | 88 | 2026 | 963 | 15.100 |
Why?
| | Vascular Stiffness | 48 | 2026 | 461 | 9.870 |
Why?
| | Oxidative Stress | 70 | 2026 | 1371 | 8.420 |
Why?
| | Exercise | 104 | 2026 | 2185 | 8.240 |
Why?
| | Vasodilation | 63 | 2025 | 519 | 7.920 |
Why?
| | Arteries | 33 | 2024 | 259 | 6.400 |
Why?
| | Sympathetic Nervous System | 69 | 2026 | 178 | 6.290 |
Why?
| | Brachial Artery | 40 | 2025 | 207 | 6.190 |
Why?
| | Blood Pressure | 106 | 2026 | 1747 | 6.040 |
Why?
| | Biomedical Research | 12 | 2024 | 705 | 4.780 |
Why?
| | Writing | 8 | 2024 | 99 | 4.530 |
Why?
| | Carotid Arteries | 29 | 2025 | 201 | 4.230 |
Why?
| | Aorta | 21 | 2026 | 432 | 4.180 |
Why?
| | Physical Endurance | 49 | 2026 | 281 | 3.810 |
Why?
| | Vascular Diseases | 15 | 2023 | 248 | 3.590 |
Why?
| | Antioxidants | 25 | 2026 | 578 | 3.450 |
Why?
| | Nitric Oxide | 34 | 2025 | 902 | 3.300 |
Why?
| | Cardiovascular Diseases | 30 | 2026 | 2095 | 3.230 |
Why?
| | Regional Blood Flow | 36 | 2020 | 506 | 3.160 |
Why?
| | Physiology | 5 | 2024 | 13 | 3.000 |
Why?
| | Publishing | 5 | 2023 | 110 | 2.950 |
Why?
| | Sodium Nitrite | 8 | 2021 | 39 | 2.910 |
Why?
| | Heart Rate | 84 | 2023 | 838 | 2.880 |
Why?
| | Postmenopause | 28 | 2026 | 378 | 2.870 |
Why?
| | Endothelial Cells | 23 | 2026 | 854 | 2.780 |
Why?
| | Resistance Training | 5 | 2023 | 177 | 2.620 |
Why?
| | Mitochondria | 12 | 2026 | 978 | 2.610 |
Why?
| | Aged | 182 | 2026 | 25297 | 2.560 |
Why?
| | Hypertension | 24 | 2025 | 1238 | 2.540 |
Why?
| | Dietary Supplements | 21 | 2026 | 571 | 2.420 |
Why?
| | Pulse Wave Analysis | 25 | 2026 | 244 | 2.310 |
Why?
| | Blood Vessels | 6 | 2020 | 174 | 2.300 |
Why?
| | Middle Aged | 205 | 2026 | 35224 | 2.290 |
Why?
| | Caloric Restriction | 10 | 2021 | 131 | 2.280 |
Why?
| | Exercise Tolerance | 10 | 2026 | 285 | 2.190 |
Why?
| | Physical Exertion | 34 | 2014 | 211 | 2.180 |
Why?
| | Cellular Senescence | 12 | 2026 | 227 | 2.160 |
Why?
| | Diet, Sodium-Restricted | 8 | 2020 | 38 | 2.130 |
Why?
| | Cardiovascular Physiological Phenomena | 14 | 2026 | 48 | 2.060 |
Why?
| | Humans | 360 | 2026 | 142675 | 2.060 |
Why?
| | Oxygen Consumption | 48 | 2026 | 717 | 2.040 |
Why?
| | Male | 268 | 2026 | 71074 | 2.040 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 203 | 1.990 |
Why?
| | Inflammation | 24 | 2024 | 2883 | 1.970 |
Why?
| | Muscles | 32 | 2023 | 332 | 1.950 |
Why?
| | Ascorbic Acid | 17 | 2025 | 180 | 1.940 |
Why?
| | Physical Fitness | 20 | 2013 | 207 | 1.940 |
Why?
| | Baroreflex | 16 | 2016 | 56 | 1.910 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 247 | 1.870 |
Why?
| | Methylamines | 6 | 2022 | 40 | 1.840 |
Why?
| | NF-kappa B | 9 | 2015 | 666 | 1.820 |
Why?
| | Peer Review | 4 | 2023 | 45 | 1.780 |
Why?
| | Superoxides | 16 | 2022 | 207 | 1.780 |
Why?
| | Vasodilator Agents | 12 | 2024 | 330 | 1.750 |
Why?
| | Acetylcholine | 12 | 2023 | 203 | 1.650 |
Why?
| | Mice | 60 | 2026 | 18309 | 1.590 |
Why?
| | Animals | 91 | 2026 | 37904 | 1.570 |
Why?
| | Norepinephrine | 29 | 2011 | 191 | 1.550 |
Why?
| | Female | 187 | 2026 | 76889 | 1.500 |
Why?
| | Adult | 204 | 2026 | 39754 | 1.500 |
Why?
| | Diet, Western | 3 | 2022 | 83 | 1.490 |
Why?
| | Heart | 16 | 2018 | 629 | 1.450 |
Why?
| | Cardiovascular System | 11 | 2026 | 139 | 1.450 |
Why?
| | Mice, Inbred C57BL | 33 | 2026 | 6007 | 1.420 |
Why?
| | Healthy Aging | 4 | 2024 | 37 | 1.400 |
Why?
| | Doxorubicin | 6 | 2026 | 387 | 1.400 |
Why?
| | Adipose Tissue | 19 | 2018 | 651 | 1.400 |
Why?
| | Vascular Resistance | 20 | 2012 | 364 | 1.370 |
Why?
| | Motor Activity | 8 | 2024 | 717 | 1.320 |
Why?
| | Salicylates | 5 | 2015 | 29 | 1.290 |
Why?
| | Respiratory Muscles | 5 | 2023 | 35 | 1.290 |
Why?
| | Forearm | 18 | 2023 | 139 | 1.280 |
Why?
| | NADPH Oxidases | 13 | 2020 | 130 | 1.250 |
Why?
| | Autonomic Nervous System | 11 | 2008 | 79 | 1.200 |
Why?
| | Research Personnel | 4 | 2023 | 180 | 1.190 |
Why?
| | Age Factors | 29 | 2025 | 3266 | 1.160 |
Why?
| | Muscle, Skeletal | 24 | 2026 | 1799 | 1.160 |
Why?
| | Reactive Oxygen Species | 14 | 2025 | 643 | 1.140 |
Why?
| | Double-Blind Method | 17 | 2025 | 1999 | 1.140 |
Why?
| | Estrogens | 8 | 2023 | 372 | 1.130 |
Why?
| | Tyrosine | 14 | 2020 | 226 | 1.100 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 35 | 1.090 |
Why?
| | Vasoconstriction | 7 | 2017 | 218 | 1.080 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 287 | 1.040 |
Why?
| | Femoral Artery | 11 | 2013 | 186 | 1.030 |
Why?
| | NAD | 5 | 2023 | 79 | 1.020 |
Why?
| | Geriatrics | 4 | 2015 | 94 | 1.000 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 1.000 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 0.990 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 141 | 0.990 |
Why?
| | Inflammation Mediators | 6 | 2025 | 511 | 0.960 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 342 | 0.960 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 61 | 0.950 |
Why?
| | Longevity | 4 | 2015 | 174 | 0.900 |
Why?
| | Metabolomics | 4 | 2021 | 718 | 0.890 |
Why?
| | Cross-Over Studies | 11 | 2026 | 591 | 0.890 |
Why?
| | Running | 17 | 2026 | 230 | 0.880 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 33 | 0.870 |
Why?
| | Interleukin-1 | 5 | 2022 | 962 | 0.870 |
Why?
| | Curcumin | 2 | 2017 | 26 | 0.870 |
Why?
| | Bottle-Nosed Dolphin | 1 | 2024 | 3 | 0.870 |
Why?
| | Elasticity | 11 | 2017 | 192 | 0.870 |
Why?
| | Drinking Water | 2 | 2022 | 96 | 0.840 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.840 |
Why?
| | Habits | 7 | 2017 | 51 | 0.840 |
Why?
| | Niacinamide | 4 | 2025 | 82 | 0.830 |
Why?
| | Women's Health | 1 | 2026 | 311 | 0.810 |
Why?
| | Trehalose | 4 | 2017 | 35 | 0.810 |
Why?
| | Career Choice | 2 | 2024 | 234 | 0.810 |
Why?
| | Cardiorespiratory Fitness | 3 | 2025 | 68 | 0.800 |
Why?
| | Financing, Organized | 1 | 2023 | 36 | 0.800 |
Why?
| | Body Composition | 30 | 2012 | 714 | 0.790 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 735 | 0.790 |
Why?
| | Physical Education and Training | 15 | 2024 | 71 | 0.790 |
Why?
| | Peer Review, Research | 1 | 2023 | 33 | 0.790 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 104 | 0.790 |
Why?
| | Compliance | 15 | 2017 | 50 | 0.790 |
Why?
| | Research Support as Topic | 1 | 2023 | 79 | 0.790 |
Why?
| | Dementia | 2 | 2025 | 294 | 0.770 |
Why?
| | Fenofibrate | 2 | 2013 | 27 | 0.770 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 108 | 0.770 |
Why?
| | Goals | 1 | 2024 | 175 | 0.760 |
Why?
| | Vaping | 1 | 2023 | 66 | 0.750 |
Why?
| | Elastin | 6 | 2023 | 84 | 0.750 |
Why?
| | Glycation End Products, Advanced | 4 | 2025 | 86 | 0.740 |
Why?
| | Young Adult | 29 | 2025 | 13817 | 0.740 |
Why?
| | Sodium, Dietary | 4 | 2013 | 37 | 0.740 |
Why?
| | Lyases | 1 | 2022 | 15 | 0.740 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 86 | 0.740 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 9 | 0.740 |
Why?
| | Renal Insufficiency, Chronic | 7 | 2025 | 645 | 0.740 |
Why?
| | Muscle Strength | 6 | 2023 | 336 | 0.730 |
Why?
| | Transcriptome | 3 | 2023 | 1034 | 0.730 |
Why?
| | Flavonols | 4 | 2026 | 26 | 0.720 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 109 | 0.720 |
Why?
| | Research Design | 4 | 2022 | 1113 | 0.720 |
Why?
| | Rest | 13 | 2007 | 128 | 0.720 |
Why?
| | Speech | 1 | 2022 | 76 | 0.710 |
Why?
| | Stress, Physiological | 12 | 2017 | 455 | 0.710 |
Why?
| | Obesity | 14 | 2023 | 3063 | 0.700 |
Why?
| | Hemodynamics | 17 | 2023 | 1115 | 0.700 |
Why?
| | Aortitis | 2 | 2011 | 10 | 0.700 |
Why?
| | Vagus Nerve | 7 | 2005 | 91 | 0.700 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.700 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.690 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.690 |
Why?
| | Spin Labels | 8 | 2020 | 56 | 0.690 |
Why?
| | Leg | 14 | 2007 | 238 | 0.690 |
Why?
| | Flavonoids | 3 | 2026 | 86 | 0.680 |
Why?
| | Models, Animal | 6 | 2024 | 389 | 0.680 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1216 | 0.670 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 349 | 0.660 |
Why?
| | Autophagy | 3 | 2017 | 285 | 0.660 |
Why?
| | Reference Values | 26 | 2021 | 805 | 0.660 |
Why?
| | Ubiquinone | 2 | 2026 | 35 | 0.650 |
Why?
| | Isometric Contraction | 14 | 1996 | 187 | 0.650 |
Why?
| | Comprehension | 1 | 2022 | 181 | 0.650 |
Why?
| | Biomarkers | 19 | 2025 | 4227 | 0.640 |
Why?
| | Life Style | 14 | 2017 | 484 | 0.640 |
Why?
| | Cardiac Output | 15 | 2004 | 176 | 0.640 |
Why?
| | Cytokines | 10 | 2019 | 2086 | 0.640 |
Why?
| | Frailty | 2 | 2024 | 185 | 0.630 |
Why?
| | Fasting | 2 | 2020 | 282 | 0.630 |
Why?
| | Nitroglycerin | 3 | 2020 | 14 | 0.630 |
Why?
| | Exercise Therapy | 9 | 2025 | 464 | 0.620 |
Why?
| | Organophosphorus Compounds | 2 | 2026 | 84 | 0.610 |
Why?
| | Spermidine | 2 | 2024 | 18 | 0.600 |
Why?
| | Nitrites | 3 | 2014 | 88 | 0.600 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 38 | 0.590 |
Why?
| | Isoproterenol | 4 | 2007 | 97 | 0.580 |
Why?
| | Overweight | 3 | 2009 | 596 | 0.580 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 95 | 0.580 |
Why?
| | Mentoring | 1 | 2021 | 154 | 0.570 |
Why?
| | Sirtuin 1 | 3 | 2016 | 35 | 0.570 |
Why?
| | Adolescent | 46 | 2023 | 22135 | 0.570 |
Why?
| | Energy Metabolism | 9 | 2007 | 936 | 0.570 |
Why?
| | Sex Characteristics | 13 | 2011 | 782 | 0.570 |
Why?
| | Lipids | 6 | 2018 | 697 | 0.560 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 571 | 0.550 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 112 | 0.540 |
Why?
| | Health Status | 3 | 2019 | 819 | 0.540 |
Why?
| | Amino Acids | 2 | 2019 | 507 | 0.540 |
Why?
| | Body Constitution | 4 | 2005 | 51 | 0.540 |
Why?
| | Blood Volume | 8 | 1998 | 65 | 0.540 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 30 | 0.540 |
Why?
| | Tunica Intima | 7 | 2006 | 76 | 0.520 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 450 | 0.520 |
Why?
| | Diet | 6 | 2024 | 1260 | 0.520 |
Why?
| | Nitroprusside | 5 | 2011 | 72 | 0.510 |
Why?
| | Epinephrine | 14 | 2007 | 154 | 0.510 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 2150 | 0.500 |
Why?
| | Serine | 2 | 2015 | 138 | 0.500 |
Why?
| | Athletes | 3 | 2026 | 409 | 0.490 |
Why?
| | Extracellular Matrix | 1 | 2021 | 561 | 0.490 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 87 | 0.490 |
Why?
| | Basal Metabolism | 4 | 2004 | 63 | 0.490 |
Why?
| | Diet Therapy | 1 | 2016 | 37 | 0.490 |
Why?
| | Muscle Contraction | 13 | 2003 | 430 | 0.490 |
Why?
| | Glucose | 4 | 2019 | 1038 | 0.490 |
Why?
| | Hand Strength | 5 | 2026 | 141 | 0.490 |
Why?
| | Primary Prevention | 1 | 2018 | 195 | 0.480 |
Why?
| | Time Factors | 21 | 2021 | 7008 | 0.470 |
Why?
| | Cognition | 3 | 2025 | 1248 | 0.470 |
Why?
| | Estradiol | 3 | 2021 | 527 | 0.470 |
Why?
| | Premenopause | 9 | 2025 | 121 | 0.460 |
Why?
| | Aniline Compounds | 3 | 2025 | 118 | 0.460 |
Why?
| | Cross-Sectional Studies | 23 | 2025 | 5726 | 0.460 |
Why?
| | Risk Factors | 20 | 2025 | 10569 | 0.450 |
Why?
| | Colorado | 7 | 2026 | 4569 | 0.440 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 18 | 0.440 |
Why?
| | Blood Glucose | 10 | 2017 | 2321 | 0.440 |
Why?
| | Reflex | 6 | 2001 | 71 | 0.430 |
Why?
| | Body Mass Index | 18 | 2015 | 2432 | 0.430 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2025 | 138 | 0.430 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 191 | 0.430 |
Why?
| | Collagen | 3 | 2021 | 466 | 0.430 |
Why?
| | Endothelium | 1 | 2014 | 118 | 0.420 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 449 | 0.420 |
Why?
| | Geriatric Assessment | 2 | 2015 | 226 | 0.410 |
Why?
| | Atherosclerosis | 1 | 2018 | 397 | 0.410 |
Why?
| | Niacin | 1 | 2013 | 16 | 0.410 |
Why?
| | Nitrates | 4 | 2022 | 97 | 0.410 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.410 |
Why?
| | Proteome | 1 | 2018 | 497 | 0.410 |
Why?
| | Vitamin B Complex | 1 | 2013 | 40 | 0.400 |
Why?
| | Hindlimb | 1 | 2014 | 136 | 0.400 |
Why?
| | Locomotion | 1 | 2014 | 103 | 0.390 |
Why?
| | Eating | 2 | 2007 | 388 | 0.390 |
Why?
| | Aortic Diseases | 1 | 2014 | 123 | 0.380 |
Why?
| | Exercise Test | 12 | 2021 | 618 | 0.380 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 228 | 0.380 |
Why?
| | Arm | 7 | 2008 | 109 | 0.380 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.370 |
Why?
| | Ganglionic Blockers | 7 | 2008 | 9 | 0.370 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 2024 | 116 | 0.370 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 65 | 0.370 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 46 | 0.360 |
Why?
| | Allopurinol | 2 | 2016 | 69 | 0.360 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 2008 | 0.360 |
Why?
| | Pressoreceptors | 6 | 2001 | 19 | 0.360 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 73 | 0.350 |
Why?
| | Arteritis | 1 | 2011 | 25 | 0.340 |
Why?
| | Adrenal Glands | 3 | 2000 | 79 | 0.340 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 140 | 0.340 |
Why?
| | C-Reactive Protein | 3 | 2022 | 417 | 0.340 |
Why?
| | Oxidants | 1 | 2011 | 104 | 0.330 |
Why?
| | Ultrasonography | 11 | 2017 | 765 | 0.330 |
Why?
| | Postural Balance | 1 | 2014 | 246 | 0.330 |
Why?
| | Systole | 6 | 2020 | 173 | 0.330 |
Why?
| | Behavior, Animal | 1 | 2014 | 511 | 0.330 |
Why?
| | Uric Acid | 1 | 2012 | 166 | 0.330 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 347 | 0.330 |
Why?
| | Athletic Performance | 2 | 2012 | 76 | 0.320 |
Why?
| | Pilot Projects | 5 | 2025 | 1830 | 0.320 |
Why?
| | Analysis of Variance | 7 | 2011 | 1301 | 0.320 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 203 | 0.310 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 175 | 0.300 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2171 | 0.300 |
Why?
| | Peroxidase | 1 | 2010 | 170 | 0.300 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 35 | 0.300 |
Why?
| | Metabolome | 3 | 2018 | 380 | 0.300 |
Why?
| | Interleukins | 2 | 2022 | 251 | 0.300 |
Why?
| | Extremities | 2 | 2001 | 141 | 0.290 |
Why?
| | Hot Temperature | 5 | 1993 | 406 | 0.290 |
Why?
| | Blood Circulation | 4 | 2021 | 44 | 0.290 |
Why?
| | Biological Availability | 4 | 2021 | 141 | 0.290 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 187 | 0.280 |
Why?
| | Vitamin D | 2 | 2017 | 398 | 0.280 |
Why?
| | Interleukin-6 | 4 | 2024 | 784 | 0.280 |
Why?
| | Healthy Volunteers | 3 | 2018 | 214 | 0.280 |
Why?
| | Cells, Cultured | 5 | 2025 | 4150 | 0.280 |
Why?
| | Endothelin-1 | 2 | 2009 | 179 | 0.280 |
Why?
| | Administration, Oral | 5 | 2015 | 834 | 0.280 |
Why?
| | Energy Intake | 6 | 2020 | 504 | 0.280 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 49 | 0.280 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 47 | 0.280 |
Why?
| | Ventricular Function, Left | 3 | 2003 | 515 | 0.280 |
Why?
| | Kidney | 7 | 2025 | 1480 | 0.280 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 578 | 0.280 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 271 | 0.280 |
Why?
| | Peroneal Nerve | 5 | 2000 | 18 | 0.280 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1892 | 0.280 |
Why?
| | Collagen Type I | 3 | 2014 | 143 | 0.280 |
Why?
| | Upper Extremity | 1 | 2009 | 111 | 0.280 |
Why?
| | Signal Transduction | 6 | 2014 | 5193 | 0.270 |
Why?
| | Posture | 6 | 2001 | 195 | 0.270 |
Why?
| | Oxygen | 11 | 2022 | 992 | 0.270 |
Why?
| | Sports | 5 | 2003 | 210 | 0.270 |
Why?
| | Hypercapnia | 2 | 2025 | 53 | 0.270 |
Why?
| | Phosphorylation | 6 | 2013 | 1746 | 0.270 |
Why?
| | Abdomen | 5 | 2004 | 140 | 0.260 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 420 | 0.260 |
Why?
| | Adiposity | 1 | 2012 | 535 | 0.260 |
Why?
| | Regression Analysis | 10 | 2011 | 995 | 0.260 |
Why?
| | Human Experimentation | 1 | 2007 | 13 | 0.260 |
Why?
| | Treatment Outcome | 7 | 2025 | 11341 | 0.260 |
Why?
| | Acetophenones | 3 | 2019 | 13 | 0.260 |
Why?
| | Trimethaphan | 5 | 2005 | 6 | 0.260 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 828 | 0.250 |
Why?
| | Swimming | 5 | 2002 | 49 | 0.250 |
Why?
| | Tunica Media | 3 | 2001 | 36 | 0.250 |
Why?
| | Phenylephrine | 5 | 2005 | 75 | 0.250 |
Why?
| | Electrocardiography | 9 | 2005 | 632 | 0.250 |
Why?
| | Congresses as Topic | 2 | 2018 | 227 | 0.250 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 240 | 0.240 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2612 | 0.240 |
Why?
| | Proteins | 3 | 2009 | 1016 | 0.240 |
Why?
| | Pyridinium Compounds | 3 | 2025 | 30 | 0.240 |
Why?
| | Hypoxia | 6 | 1999 | 1193 | 0.240 |
Why?
| | Case-Control Studies | 5 | 2026 | 3601 | 0.240 |
Why?
| | Sulfonamides | 3 | 2025 | 569 | 0.240 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 555 | 0.240 |
Why?
| | Chemokine CXCL12 | 1 | 2026 | 89 | 0.240 |
Why?
| | Fatty Acids | 2 | 2019 | 449 | 0.240 |
Why?
| | Microcirculation | 2 | 2019 | 137 | 0.230 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 272 | 0.230 |
Why?
| | Trastuzumab | 1 | 2026 | 104 | 0.230 |
Why?
| | Thermogenesis | 1 | 2005 | 45 | 0.230 |
Why?
| | Carbon Dioxide | 3 | 2023 | 239 | 0.230 |
Why?
| | Brain | 6 | 2023 | 2886 | 0.230 |
Why?
| | Recovery of Function | 4 | 2017 | 691 | 0.230 |
Why?
| | Aged, 80 and over | 14 | 2025 | 8009 | 0.230 |
Why?
| | Pyruvaldehyde | 1 | 2025 | 50 | 0.230 |
Why?
| | Sodium Bicarbonate | 1 | 2025 | 46 | 0.230 |
Why?
| | Receptors, Adrenergic, alpha | 2 | 2002 | 19 | 0.220 |
Why?
| | Cell Nucleus | 1 | 2008 | 612 | 0.220 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 40 | 0.220 |
Why?
| | MicroRNAs | 1 | 2011 | 692 | 0.220 |
Why?
| | Arginine | 1 | 2006 | 265 | 0.220 |
Why?
| | American Heart Association | 2 | 2020 | 298 | 0.220 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 44 | 0.220 |
Why?
| | Mitochondria, Muscle | 1 | 2026 | 121 | 0.210 |
Why?
| | Preventive Medicine | 2 | 2015 | 40 | 0.210 |
Why?
| | Acidosis | 1 | 2025 | 104 | 0.210 |
Why?
| | Veins | 5 | 2009 | 69 | 0.210 |
Why?
| | Apigenin | 1 | 2023 | 3 | 0.210 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.200 |
Why?
| | Skin | 4 | 2019 | 755 | 0.200 |
Why?
| | Lactates | 7 | 2007 | 83 | 0.200 |
Why?
| | Weight Loss | 2 | 2008 | 819 | 0.200 |
Why?
| | History, 21st Century | 1 | 2024 | 219 | 0.200 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 79 | 0.200 |
Why?
| | Blueberry Plants | 1 | 2023 | 7 | 0.200 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 82 | 0.200 |
Why?
| | Hand | 8 | 1994 | 160 | 0.190 |
Why?
| | History, 20th Century | 1 | 2024 | 323 | 0.190 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 413 | 0.190 |
Why?
| | Apoptosis | 1 | 2011 | 2431 | 0.190 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 199 | 0.190 |
Why?
| | Cholesterol | 5 | 1997 | 397 | 0.190 |
Why?
| | Myocardium | 5 | 2010 | 938 | 0.190 |
Why?
| | Anthropometry | 3 | 2011 | 203 | 0.190 |
Why?
| | Kidney Diseases | 2 | 2025 | 417 | 0.190 |
Why?
| | Acetylene | 2 | 2003 | 4 | 0.190 |
Why?
| | Authorship | 1 | 2023 | 48 | 0.180 |
Why?
| | Supine Position | 6 | 1999 | 38 | 0.180 |
Why?
| | Fibrinolysis | 2 | 2008 | 162 | 0.180 |
Why?
| | Sugars | 1 | 2022 | 41 | 0.180 |
Why?
| | Adrenal Medulla | 1 | 2002 | 9 | 0.180 |
Why?
| | Respiration | 7 | 1998 | 209 | 0.180 |
Why?
| | Cold Temperature | 7 | 2001 | 202 | 0.180 |
Why?
| | Coronary Disease | 6 | 1998 | 368 | 0.180 |
Why?
| | Citrulline | 1 | 2022 | 46 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2023 | 253 | 0.180 |
Why?
| | Universities | 1 | 2024 | 450 | 0.170 |
Why?
| | Body Weight | 10 | 2019 | 989 | 0.170 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 165 | 0.170 |
Why?
| | Sirolimus | 3 | 2021 | 277 | 0.170 |
Why?
| | Progesterone | 1 | 2002 | 255 | 0.170 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 51 | 0.170 |
Why?
| | Cancer Survivors | 1 | 2026 | 300 | 0.170 |
Why?
| | Nicotine | 1 | 2023 | 331 | 0.170 |
Why?
| | Insulin | 11 | 2022 | 2498 | 0.170 |
Why?
| | Fatty Liver | 1 | 2023 | 255 | 0.170 |
Why?
| | Weight Gain | 1 | 2004 | 555 | 0.170 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 86 | 0.170 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.160 |
Why?
| | Mexican Americans | 1 | 2001 | 114 | 0.160 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 120 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 159 | 0.160 |
Why?
| | Knee | 1 | 2000 | 69 | 0.160 |
Why?
| | DNA Methylation | 2 | 2024 | 667 | 0.160 |
Why?
| | Lipocalin-2 | 1 | 2020 | 79 | 0.160 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 139 | 0.160 |
Why?
| | Triglycerides | 4 | 2017 | 517 | 0.160 |
Why?
| | Lung | 4 | 1999 | 4131 | 0.150 |
Why?
| | Fibrinogen | 2 | 1998 | 179 | 0.150 |
Why?
| | RNA, Untranslated | 1 | 2021 | 123 | 0.150 |
Why?
| | Emotions | 1 | 2025 | 571 | 0.150 |
Why?
| | Functional Food | 1 | 2019 | 4 | 0.150 |
Why?
| | Menopause | 2 | 2006 | 315 | 0.150 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 429 | 0.150 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 37 | 0.150 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 27 | 0.150 |
Why?
| | Mentors | 1 | 2021 | 211 | 0.150 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 42 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 375 | 0.150 |
Why?
| | Rats | 11 | 2015 | 5570 | 0.150 |
Why?
| | Sex Factors | 4 | 2025 | 2066 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 58 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 481 | 0.150 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 48 | 0.150 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 750 | 0.140 |
Why?
| | Social Class | 1 | 2001 | 269 | 0.140 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 26 | 0.140 |
Why?
| | Stroke Volume | 7 | 1998 | 610 | 0.140 |
Why?
| | Linear Models | 2 | 2012 | 853 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2020 | 265 | 0.140 |
Why?
| | Cohort Studies | 5 | 2013 | 5820 | 0.140 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 363 | 0.140 |
Why?
| | Cardiology | 1 | 2020 | 283 | 0.130 |
Why?
| | Leptin | 5 | 2019 | 240 | 0.130 |
Why?
| | Methionine | 1 | 2018 | 159 | 0.130 |
Why?
| | Adipocytes | 1 | 2019 | 221 | 0.130 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 140 | 0.130 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 56 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2021 | 393 | 0.130 |
Why?
| | Calcitriol | 1 | 2017 | 56 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 60 | 0.130 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 65 | 0.130 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 32 | 0.130 |
Why?
| | Heart Conduction System | 4 | 2002 | 91 | 0.120 |
Why?
| | Stress, Psychological | 3 | 1995 | 1135 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4528 | 0.120 |
Why?
| | Hyperuricemia | 1 | 2016 | 47 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 1833 | 0.120 |
Why?
| | Education, Graduate | 1 | 2016 | 35 | 0.120 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 119 | 0.120 |
Why?
| | Students, Health Occupations | 1 | 2016 | 35 | 0.120 |
Why?
| | Age Distribution | 1 | 1997 | 394 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1998 | 270 | 0.120 |
Why?
| | Insulin Resistance | 3 | 2018 | 1253 | 0.120 |
Why?
| | Methemoglobin | 1 | 2015 | 24 | 0.120 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 320 | 0.120 |
Why?
| | Walking | 3 | 2011 | 558 | 0.120 |
Why?
| | Risk Assessment | 2 | 2018 | 3533 | 0.120 |
Why?
| | Myocardial Contraction | 3 | 1988 | 298 | 0.120 |
Why?
| | Program Development | 1 | 2018 | 364 | 0.120 |
Why?
| | Hemostasis | 2 | 1998 | 101 | 0.120 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 52 | 0.110 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 28 | 0.110 |
Why?
| | Middle Cerebral Artery | 2 | 2025 | 55 | 0.110 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 8 | 0.110 |
Why?
| | Urinalysis | 1 | 2015 | 80 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 521 | 0.110 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 10 | 0.110 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 10 | 0.110 |
Why?
| | Skinfold Thickness | 4 | 1999 | 43 | 0.110 |
Why?
| | Rotenone | 1 | 2014 | 16 | 0.110 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 254 | 0.110 |
Why?
| | Rejuvenation | 1 | 2014 | 19 | 0.110 |
Why?
| | Nutritional Status | 1 | 2016 | 350 | 0.100 |
Why?
| | Neurons | 2 | 1995 | 1613 | 0.100 |
Why?
| | Mobility Limitation | 1 | 2014 | 63 | 0.100 |
Why?
| | Plasma Volume | 3 | 2002 | 19 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 94 | 0.100 |
Why?
| | Liver | 3 | 2017 | 1838 | 0.100 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 128 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1493 | 0.100 |
Why?
| | Plethysmography | 4 | 2007 | 109 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 938 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2026 | 2334 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 120 | 0.100 |
Why?
| | Epidemiology | 1 | 2013 | 33 | 0.100 |
Why?
| | Cell Cycle | 1 | 2016 | 625 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2011 | 279 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 251 | 0.100 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 74 | 0.100 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 277 | 0.100 |
Why?
| | Administration, Sublingual | 1 | 2012 | 12 | 0.090 |
Why?
| | Body Temperature | 5 | 1991 | 223 | 0.090 |
Why?
| | Pyrogallol | 1 | 2012 | 3 | 0.090 |
Why?
| | Hypotension | 1 | 1993 | 126 | 0.090 |
Why?
| | Catecholamines | 5 | 1996 | 89 | 0.090 |
Why?
| | Mental Processes | 1 | 1992 | 38 | 0.090 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 12 | 0.090 |
Why?
| | Ribonucleotides | 1 | 2012 | 26 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 7845 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 118 | 0.090 |
Why?
| | Waist Circumference | 1 | 2012 | 139 | 0.090 |
Why?
| | Naphthols | 1 | 2011 | 6 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 137 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 4 | 0.090 |
Why?
| | Nitroso Compounds | 1 | 2011 | 7 | 0.090 |
Why?
| | Myography | 1 | 2011 | 10 | 0.090 |
Why?
| | Metabolism | 2 | 2001 | 44 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 115 | 0.090 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 77 | 0.090 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 18 | 0.080 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 17 | 0.080 |
Why?
| | Diastole | 3 | 2003 | 141 | 0.080 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 374 | 0.080 |
Why?
| | Connective Tissue | 1 | 2010 | 39 | 0.080 |
Why?
| | Endorphins | 1 | 1990 | 9 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 398 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2022 | 16647 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.080 |
Why?
| | Caspases | 1 | 2011 | 234 | 0.080 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1090 | 0.080 |
Why?
| | United States | 3 | 2020 | 15496 | 0.080 |
Why?
| | Decompression | 1 | 1990 | 3 | 0.080 |
Why?
| | Benzamides | 1 | 2011 | 223 | 0.080 |
Why?
| | Phosphoproteins | 1 | 2012 | 338 | 0.080 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 89 | 0.080 |
Why?
| | Fibronectins | 1 | 2010 | 136 | 0.080 |
Why?
| | Communication | 1 | 2016 | 953 | 0.080 |
Why?
| | Phenotype | 2 | 2024 | 3160 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5276 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 256 | 0.080 |
Why?
| | Diet Records | 1 | 2009 | 84 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 1032 | 0.070 |
Why?
| | Subclavian Artery | 1 | 1989 | 28 | 0.070 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 26 | 0.070 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 63 | 0.070 |
Why?
| | Leukocyte Count | 1 | 2010 | 316 | 0.070 |
Why?
| | Acclimatization | 1 | 1990 | 171 | 0.070 |
Why?
| | Prognosis | 1 | 2018 | 4159 | 0.070 |
Why?
| | Probability | 1 | 2010 | 300 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 141 | 0.070 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.070 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 3 | 0.070 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.070 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 19 | 0.070 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 29 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 264 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2509 | 0.070 |
Why?
| | Homeostasis | 3 | 2021 | 635 | 0.070 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 75 | 0.070 |
Why?
| | Aortic Coarctation | 1 | 1989 | 78 | 0.070 |
Why?
| | Propranolol | 4 | 2001 | 45 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 864 | 0.070 |
Why?
| | Leukocytes | 1 | 2010 | 293 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 260 | 0.070 |
Why?
| | Calorimetry, Indirect | 2 | 2005 | 86 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 148 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 420 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2011 | 789 | 0.070 |
Why?
| | Hyperemia | 1 | 1988 | 48 | 0.070 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 141 | 0.070 |
Why?
| | Hyperoxia | 2 | 1999 | 99 | 0.060 |
Why?
| | Catalase | 1 | 2007 | 134 | 0.060 |
Why?
| | Electrophysiology | 3 | 1993 | 215 | 0.060 |
Why?
| | Databases, Factual | 1 | 2013 | 1452 | 0.060 |
Why?
| | Kinetics | 3 | 1997 | 1613 | 0.060 |
Why?
| | Amidohydrolases | 1 | 2006 | 32 | 0.060 |
Why?
| | Telomere | 1 | 2010 | 283 | 0.060 |
Why?
| | Gene Expression | 1 | 2011 | 1502 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 369 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2905 | 0.060 |
Why?
| | Hormones | 2 | 2002 | 136 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2001 | 223 | 0.060 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 146 | 0.060 |
Why?
| | Body Fat Distribution | 1 | 2005 | 46 | 0.060 |
Why?
| | Hematocrit | 2 | 1997 | 105 | 0.060 |
Why?
| | Heart Ventricles | 3 | 2003 | 750 | 0.060 |
Why?
| | Codon | 1 | 2005 | 91 | 0.060 |
Why?
| | Arterioles | 1 | 2025 | 56 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 46 | 0.060 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 9 | 0.060 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 12 | 0.060 |
Why?
| | Fibroblasts | 1 | 2010 | 1028 | 0.060 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 6 | 0.050 |
Why?
| | Vital Capacity | 2 | 2000 | 311 | 0.050 |
Why?
| | Vasopressins | 1 | 2005 | 60 | 0.050 |
Why?
| | Thigh | 2 | 2003 | 48 | 0.050 |
Why?
| | Calorimetry | 1 | 2004 | 70 | 0.050 |
Why?
| | Loneliness | 1 | 2025 | 58 | 0.050 |
Why?
| | Imidazoles | 1 | 2025 | 249 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1349 | 0.050 |
Why?
| | Osmolar Concentration | 3 | 2001 | 167 | 0.050 |
Why?
| | Up-Regulation | 1 | 2007 | 859 | 0.050 |
Why?
| | Postprandial Period | 1 | 2004 | 114 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2516 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 621 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 123 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1216 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2172 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1503 | 0.050 |
Why?
| | Powders | 1 | 2023 | 44 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2011 | 2831 | 0.050 |
Why?
| | Butanols | 1 | 2022 | 6 | 0.050 |
Why?
| | Hexanols | 1 | 2022 | 7 | 0.050 |
Why?
| | Biology | 1 | 2023 | 91 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 133 | 0.050 |
Why?
| | Femur | 2 | 2001 | 270 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 2034 | 0.050 |
Why?
| | Evans Blue | 1 | 2002 | 8 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 320 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 111 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 5 | 0.050 |
Why?
| | Electromyography | 3 | 1989 | 414 | 0.050 |
Why?
| | Phentolamine | 1 | 2001 | 20 | 0.040 |
Why?
| | Mesentery | 1 | 2002 | 45 | 0.040 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 33 | 0.040 |
Why?
| | Ischemia | 5 | 1994 | 416 | 0.040 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 62 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2775 | 0.040 |
Why?
| | Genotype | 1 | 2007 | 1828 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 565 | 0.040 |
Why?
| | Men | 1 | 2001 | 22 | 0.040 |
Why?
| | Acarbose | 1 | 2021 | 2 | 0.040 |
Why?
| | Lactic Acid | 4 | 1995 | 303 | 0.040 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 22 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2001 | 18 | 0.040 |
Why?
| | Tidal Volume | 2 | 1993 | 112 | 0.040 |
Why?
| | Neurons, Afferent | 2 | 1993 | 102 | 0.040 |
Why?
| | Models, Biological | 2 | 2004 | 1826 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 181 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1037 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 230 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 89 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 41 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 131 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 369 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2587 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 469 | 0.040 |
Why?
| | Thinness | 1 | 2000 | 99 | 0.040 |
Why?
| | Mexico | 1 | 2001 | 230 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 72 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 268 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 499 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2083 | 0.040 |
Why?
| | NADP | 1 | 2019 | 51 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 6 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 1077 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 680 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 25 | 0.040 |
Why?
| | Hyperinsulinism | 1 | 2019 | 114 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 500 | 0.040 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 15 | 0.030 |
Why?
| | Prevalence | 2 | 2005 | 2805 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2024 | 848 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 85 | 0.030 |
Why?
| | Biological Transport | 1 | 2019 | 411 | 0.030 |
Why?
| | Acute Disease | 1 | 2000 | 994 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 92 | 0.030 |
Why?
| | Mathematics | 2 | 1996 | 99 | 0.030 |
Why?
| | Automation | 1 | 1997 | 102 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 153 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 16 | 0.030 |
Why?
| | Echocardiography | 2 | 2005 | 641 | 0.030 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 12 | 0.030 |
Why?
| | Cell Respiration | 1 | 2017 | 107 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1320 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2016 | 27 | 0.030 |
Why?
| | Weight Lifting | 3 | 1988 | 32 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 115 | 0.030 |
Why?
| | Myoblasts | 1 | 2017 | 84 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 213 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 202 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 238 | 0.030 |
Why?
| | Pain | 2 | 1992 | 771 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 208 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 194 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1501 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 12 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 51 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2930 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 41 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 25 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 133 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 308 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 80 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 60 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 27 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 199 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 306 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 61 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 4 | 0.030 |
Why?
| | Health | 1 | 2014 | 83 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 238 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 310 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3362 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 19 | 0.030 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 30 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 534 | 0.020 |
Why?
| | Educational Measurement | 1 | 2016 | 319 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2015 | 305 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 862 | 0.020 |
Why?
| | Reflex, Stretch | 1 | 1993 | 10 | 0.020 |
Why?
| | Denervation | 1 | 1993 | 27 | 0.020 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 13 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 446 | 0.020 |
Why?
| | Venous Pressure | 1 | 1992 | 5 | 0.020 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 52 | 0.020 |
Why?
| | Endoribonucleases | 1 | 2013 | 79 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 773 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 538 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 1995 | 287 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1993 | 328 | 0.020 |
Why?
| | Fingers | 1 | 2013 | 106 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 628 | 0.020 |
Why?
| | Skin Temperature | 1 | 1992 | 30 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 160 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2884 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 9 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 195 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 262 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 74 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 3 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 329 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 22 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 152 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 2 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 446 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 777 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 78 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 161 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 33 | 0.020 |
Why?
| | Fever | 1 | 1990 | 308 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 140 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 351 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 10 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 177 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 26 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 40 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 5 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1049 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 365 | 0.020 |
Why?
| | Child | 3 | 1997 | 22376 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 199 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 491 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1172 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 636 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 397 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 40 | 0.010 |
Why?
| | Fatigue | 1 | 1988 | 352 | 0.010 |
Why?
| | Environmental Exposure | 1 | 1991 | 583 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1990 | 700 | 0.010 |
Why?
| | Syncope | 1 | 1986 | 55 | 0.010 |
Why?
| | Blood Proteins | 1 | 1988 | 245 | 0.010 |
Why?
| | Feedback | 1 | 2005 | 181 | 0.010 |
Why?
| | Anabolic Agents | 1 | 1984 | 12 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 60 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 436 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1655 | 0.010 |
Why?
| | Affect | 1 | 2007 | 310 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1984 | 100 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3110 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 345 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 186 | 0.010 |
Why?
| | Methods | 1 | 1983 | 65 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 11 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 187 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 168 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 2 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 606 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 20 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 400 | 0.010 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2001 | 53 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 141 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 19 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 18 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 42 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 197 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 498 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 116 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 36 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 253 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 57 | 0.000 |
Why?
| | Pain Measurement | 1 | 1992 | 547 | 0.000 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.000 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.000 |
Why?
| | Glycerol | 1 | 1988 | 89 | 0.000 |
Why?
| | Growth Hormone | 1 | 1988 | 98 | 0.000 |
Why?
| | Thyroid Hormones | 1 | 1988 | 67 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 158 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 318 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 9 | 0.000 |
Why?
| | Risk | 1 | 1987 | 897 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 120 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 62 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 500 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 423 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 1073 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|